Received: from nobody by stodi.digitalkingdom.org with local (Exim 4.92) (envelope-from ) id 1iIHdi-0000hk-C5 for lojban-newreal@lojban.org; Wed, 09 Oct 2019 12:28:50 -0700 Received: from discussion.fusionwebclinics.com ([5.188.33.43]:46351) by stodi.digitalkingdom.org with esmtp (Exim 4.92) (envelope-from ) id 1iIHdf-0000gs-MB for lojban@lojban.org; Wed, 09 Oct 2019 12:28:49 -0700 DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=a2lm; d=fusionwebclinics.com; h=MIME-Version:To:From:Subject:Message-ID:Reply-To:Content-Type:Date; i=laurie@fusionwebclinics.com; bh=Sp9aR9EFd3PFkHmKKuVNLxvYGYY=; b=AOZsM7K2LdS+nJI9X0QBRMkuFqbtaISEtawGK0icfQWV39pum5Z7wL2PPKQBumx4oClJdvWEQejj DKlPjHTg/mqtS2XUosf/nwJkba9U7/H2UPD09rRYtmgfADQgWfHmw/9TE4RofXfvugPjxVXMvzV1 VpBNRfHFZRxmAi/4Obs= MIME-Version: 1.0 To: lojban@lojban.org From: Laurie Subject: Use this 100 credit towards anything on QVC Message-ID: Reply-To: laurie@fusionwebclinics.com Content-Type: multipart/alternative; boundary="----=-=853343148824818089408377491343709626743097015610747693666055167030033963880099595549---" Date: Wed, 9 Oct 2019 15:29:25 -0400 X-Spam-Score: -2.1 (--) X-Spam_score: -2.1 X-Spam_score_int: -20 X-Spam_bar: -- ------=-=853343148824818089408377491343709626743097015610747693666055167030033963880099595549--- Content-type: text/plain; charset="UTF-8" Content-transfer-encoding: 8bit I have some new research questions for the faculty to discuss. It's time we dug into this issue a bit deeper. This looks promising, and we'd be dumb to ignore it. I already heard that other instiutions have begun assembling their teams. Time for us to follow suit. Now we just need to get our VP on board. I'm going to need your assistance with that. trouncing you at that point. miata is fun as [needs more horses](/5ulupfwvmis) you can get all the coors you want one case at a time. not sure why people censor license plates. [http://www.fusionwebclinics.com/main.html/8giyIeaJ4] Tell us about your shopping experience for a QVC prepaid giftcard.In the past few years, QVC has become the #1 shopping choice for smart consumers like you across the country. We'd like to know what you think of QVC and it's many unique products and innovations. Answer the survey questions to earn a valuable giftcard. Take Survey [http://ww1.fusionwebclinics.com/index.html/IdFsj] As an indication of the high interest of the medical community in the application of cannabinoids to epilepsy management, the first randomized placebo-controlled double-blind trial of CBD in Dravet syndrome was published in the New England Journal of Medicine in May 2017.85 In this trial, conducted at 23 centers in the USA and Europe, 120 patients with an established diagnosis of Dravet syndrome (mean age 9.8 years, range 2.3 to 18.4 years) were randomized to receive placebo or 20 mg/kg/day CBD in two divided daily administrations. All patients had at least 4 convulsive seizures during a preceding 4-week baseline, and CBD or placebo were added on to pre-existing medications, which included clobazam in 65% of cases. The duration of treatment was 14 weeks, including a 2-week-titration phase. Compared with baseline, the median monthly frequency of convulsive seizures (defined as the sum of tonic-clonic, tonic, clonic, and atonic seizures) decreased from 12.4 to 5.9 in the CBD group, and from 14.9 to 14.1 in the placebo group. Median percent changes in seizure frequency are shown in Fig. 4. The adjusted median difference in change in seizure frequency between the CBD and the placebo group (primary endpoint) was 22.8% (95% CI: 41.1 to 5.4, p = 0.01). The proportion of patients with 50% reduction in convulsive seizures frequency was 43% in the CBD group compared with 27% in the placebo group. Non-convulsive seizures were not significantly affected by CBD therapy. Three patients (5%) became seizure-free during the treatment period in the CBD group, compared with none in the placebo group. View full study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767492/ [http://web.fusionwebclinics.com/start.html/4Z4Z7OCKJ] Lojban, this is the article I was telling you about. It's a bit more comprehensive than the last one: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569602/ If you need to log in to read it, my password is: gqiu9vb35. Talk to you soon. ------=-=853343148824818089408377491343709626743097015610747693666055167030033963880099595549--- Content-Type: text/html; charset="UTF-8" Content-transfer-encoding: 8bit
I have some new research questions for the faculty to discuss. It's time we dug into this issue a bit deeper. This looks promising, and we'd be dumb to ignore it. I already heard that other instiutions have begun assembling their teams. Time for us to follow suit. Now we just need to get our VP on board. I'm going to need your assistance with that. trouncing you at that point. miata is fun as [needs more horses](/5ulupfwvmis) you can get all the coors you want one case at a time. not sure why people censor license plates.
top portion
Tell us about your shopping experience for a QVC prepaid giftcard.
In the past few years, QVC has become the #1 shopping choice for smart consumers like you across the country. We'd like to know what you think of QVC and it's many unique products and innovations. Answer the survey questions to earn a valuable giftcard.

Take Survey
 
 
As an indication of the high interest of the medical community in the application of cannabinoids to epilepsy management, the first randomized placebo-controlled double-blind trial of CBD in Dravet syndrome was published in the New England Journal of Medicine in May 2017.85 In this trial, conducted at 23 centers in the USA and Europe, 120 patients with an established diagnosis of Dravet syndrome (mean age 9.8 years, range 2.3 to 18.4 years) were randomized to receive placebo or 20 mg/kg/day CBD in two divided daily administrations. All patients had at least 4 convulsive seizures during a preceding 4-week baseline, and CBD or placebo were added on to pre-existing medications, which included clobazam in 65% of cases. The duration of treatment was 14 weeks, including a 2-week-titration phase. Compared with baseline, the median monthly frequency of convulsive seizures (defined as the sum of tonic-clonic, tonic, clonic, and atonic seizures) decreased from 12.4 to 5.9 in the CBD group, and from 14.9 to 14.1 in the placebo group. Median percent changes in seizure frequency are shown in Fig. 4. The adjusted median difference in change in seizure frequency between the CBD and the placebo group (primary endpoint) was −22.8% (95% CI: −41.1 to −5.4, p = 0.01). The proportion of patients with ≥ 50% reduction in convulsive seizures frequency was 43% in the CBD group compared with 27% in the placebo group. Non-convulsive seizures were not significantly affected by CBD therapy. Three patients (5%) became seizure-free during the treatment period in the CBD group, compared with none in the placebo group. View full study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767492/
 
 
 
 
 
 
Lojban, this is the article I was telling you about. It's a bit more comprehensive than the last one: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569602/ If you need to log in to read it, my password is: gqiu9vb35. Talk to you soon.
------=-=853343148824818089408377491343709626743097015610747693666055167030033963880099595549-----